Nexilico
Nexilico, Inc. is a Danville, California-based biotech company developing AI-driven computational platforms for gut microbiome precision medicine. Its proprietary microbiome digital twin technology runs large-scale in silico simulations, serving pharmaceutical and biotech firms via licensing and collaborative development agreements.
- Company typePrivate
- Founded2019
- HeadquartersBerkeley, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Nexilico does
Nexilico, Inc. is a privately held biotech company founded in 2019 and headquartered at 98 Amberfield Ln, Danville, California (previously listed in Berkeley). The company develops AI-driven computational platforms for gut microbiome precision medicine, anchored by its proprietary "microbiome digital twin" technology. This modality-agnostic platform runs massively parallel in silico simulations of microbial community dynamics under therapeutic perturbations, capturing interactions across thousands of metabolic features and tracking how microbial strains respond to interventions over time. As of July 2025 the platform had executed over 1.5 million virtual experiments and 40 billion metabolic calculations, producing what the company describes as the largest virtual microbiome dataset to date.
The company's core product, the Microbiome Digital Twin Platform, is built on mathematical, biophysical, and systems biology algorithms and underpins several specialized research programs: an AI-Driven Discovery Platform for precision microbiome therapeutics (NSF Phase II SBIR funded), a Gut Microbiome Drug Metabolism Prediction solution (NIH NCATS funded in collaboration with UC Berkeley and Microvi Biotech), a Gut Microbiome Response Prediction Platform (NIH NIGMS funded), and a Xenobiotic Toxicity Solution initially targeting arsenic detoxification (NIH NIEHS STTR funded). These applications span therapeutic areas including necrotizing enterocolitis (with Siolta Therapeutics), metabolic disorders, oncology, and inflammatory diseases.
Nexilico operates a B2B technology platform model serving pharmaceutical and biotech companies developing microbiome-based therapeutics and live biotherapeutic products. Revenue mechanics are pre-commercial: the company funds R&D almost entirely through non-dilutive NIH and NSF SBIR/STTR grants (cumulative identified government funding exceeds $3M since 2019, including a $1M NSF Phase II award in 2023), supplemented by collaborative development agreements with potential milestone and royalty economics (notably the Siolta Therapeutics co-development deal announced September 2024), and technology licensing intent. Infrastructure is supported by AWS Activate, NVIDIA Inception Program (joined March 2024), and Google for Startups Cloud Program at the Scale Tier (joined April 2025, up to $350K in cloud credits). The company has 1-10 employees, is led by co-founder and CEO Mohammad Soheilypour and Director of R&D Wyatt Hartman, and has no disclosed equity venture capital investors.
Nexilico firmographics
Firmographics- Name
- Nexilico
- Legal name
- Nexilico, Inc.
- Website
- https://nexilico.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nexilico, Inc. is a Danville, California-based biotech company developing AI-driven computational platforms for gut microbiome precision medicine. Its proprietary microbiome digital twin technology runs large-scale in silico simulations, serving pharmaceutical and biotech firms via licensing and collaborative development agreements.
- Ownership category
- akta.pro rank
Nexilico industry classification
Industry- Product category
- Computational Biology / Microbiome Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Nexilico is headquartered
LocationHeadquarters
- HQ city
- Berkeley
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nexilico business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Technology Licensing: Licensing of AI-driven microbiome discovery platform and digital twin technology to pharmaceutical and biotech companies for drug discovery and development.
- Collaborative Development Agreements: Partnerships with other biotech companies (e.g., Siolta Therapeutics) for co-development of microbiome-based therapeutics with potential milestone and royalty payments.
- Government Grants and SBIR Funding: NIH and NSF SBIR/STTR grants providing non-dilutive funding for R&D activities across multiple therapeutic areas.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Nexilico product offering
Product offeringCore offering
Nexilico develops and operates a proprietary Microbiome Digital Twin Platform—an AI-driven, massively parallel computational platform that simulates the dynamic behavior of microbial communities under perturbations, capturing thousands of metabolic features and tracking strain-level responses over time. The platform powers a modality-agnostic discovery engine for designing precision microbiome therapeutics across multiple disease areas (e.g., necrotizing enterocolitis, drug metabolism, xenobiotic toxicity). It has completed over 1.5 million virtual experiments and 40 billion metabolic calculations, providing biotech, pharma, and research collaborators with in silico prediction capabilities that reduce reliance on costly trial-and-error laboratory studies.
Product overview
Nexilico is a biotech company offering a unified precision microbiome engineering platform powered by proprietary AI-driven technology. The core offering consists of the Microbiome Digital Twin Platform, which enables virtualized microbiome experimentation at population scale through in silico simulations (over 1.5 million simulations and 40 billion metabolic calculations). This platform serves as the foundation for specialized applications including the AI-Driven Discovery Platform for precision microbiome therapeutics, the Gut Microbiome Response Prediction Platform for personalized therapeutic response modeling, the Gut Microbiome Drug Metabolism Prediction solution, and the Xenobiotic Toxicity Solution for environmental toxin neutralization. The platform is modality-agnostic, supporting development of diverse therapeutic strategies across multiple disease areas including necrotizing enterocolitis (in partnership with Siolta Therapeutics), metabolic disorders, oncology, and inflammatory diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Microbiome Digital Twin Platform A massively parallel simulation platform that models the dynamic behavior of microbial communities under perturbations, capturing interactions across thousands of metabolic features and tracking how microbial strains respond to changes over time. Built on mathematical, biophysical, and systems biology algorithms, it produces the largest virtual microbiome dataset to date. Used by biotech, pharma, and academic collaborators to virtualize microbiome experimentation.
- AI-Driven Discovery Platform A computational discovery platform based on microbiome digital twin technology that enables disease-agnostic design of precision microbiome therapeutics with enhanced effectiveness as evaluated through microbiome signatures and clinical response. Targeted at biotech and pharmaceutical companies seeking to accelerate microbiome-targeted therapeutic development.
- Precision Microbiome Engineering Platform A modality-agnostic AI-driven discovery platform that enables microbiome precision medicine and drives the development of diverse therapeutic strategies across a range of diseases, incorporating proprietary microbiome digital twin technology. Designed for biotech and pharma partners seeking integrated precision microbiome engineering capabilities.
Quantifiable outcome
- 1.5 million virtual experiments completed and 40 billion metabolic calculations simulated
- +2 more outcomes
Companies that use Nexilico
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Nexilico technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Nexilico partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered supporting, major and core.
- AWS ActivatesupportingAWS Activate program providing cloud infrastructure and technical resources that enabled scaling of in silico microbiome simulations to 1.5 million experiments.
- Google for StartupsmajorAccepted into Google for Startups Cloud Program at Scale Tier, gaining access to up to $350,000 in Google Cloud credits, expert mentorship, exclusive technical resources, go-to-market guidance, and direct integration with Google Cloud's AI/ML ecosystem.
- Siolta TherapeuticscoreCollaboration agreement to address necrotizing enterocolitis (NEC) using innovative microbial therapeutics. Combines Nexilico's modality-agnostic AI-driven discovery platform with Siolta's end-to-end live biotherapeutic product (LBP) platform. Aims to develop multistrain LBP for preterm infants.
- NVIDIAmajorAccepted into NVIDIA Inception Program for AI startups, providing access to advanced computing technologies, expertise, and global network of venture capitalists to accelerate microbiome engineering technology.
- University of California BerkeleycoreCollaboration with UC Berkeley and Microvi Biotech on NIH NCATS grant to develop computational solution for predicting gut microbiome-mediated drug metabolism and its effect on drug efficacy and toxicity.
- Microvi Biotech Inc.coreCollaboration on developing precision biological processes combining Microvi's MicroNiche Engineering (MNE) Platform with Nexilico's machine learning and microbiome modeling platforms. Multiple NIH SBIR grants awarded ($1.12M NIEHS, NCATS funding) for microbiome-based technology development.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Nexilico competitors and assessment
Company assessmentDirect peers
- Second Genome: Second Genome applies microbiome science to drug discovery in inflammation and metabolic disease, combining computational biology with therapeutic development — a similar platform-plus-pipeline model to Nexilico's digital twin approach.
- Microvi Biotech: Microvi Biotech provides microbiome-based biocatalysis and precision biological processes, and is Nexilico's repeated NIH co-awardee. Both target microbiome engineering for environmental and biomedical applications, sharing grant funding and research collaboration.
- Insitro: Insitro combines machine learning with high-throughput biology to discover and develop therapeutics. Like Nexilico, Insitro uses AI-driven predictive modeling as a core platform asset to accelerate drug discovery across multiple indications.
- Siolta Therapeutics: Siolta Therapeutics develops live biotherapeutic products for inflammatory diseases, including NEC — Nexilico's named collaboration partner. Both companies operate in the microbiome therapeutics space with complementary platforms (computational discovery vs. LBP development).
- Vedanta Biosciences: Vedanta Biosciences is a clinical-stage microbiome therapeutics company developing defined bacterial consortia for immune-mediated diseases. Comparable as a microbiome drug discovery company pursuing live biotherapeutics, though at significantly larger scale.
Emerging players
- Turbine AI: Turbine builds AI-driven simulation platforms for cell biology and drug discovery, including in silico experiments on cancer cell behavior. Comparable to Nexilico as an AI simulation platform applied to life sciences R&D, though focused on oncology rather than microbiome.
- CytoReason: CytoReason builds AI models of the human immune system and disease biology used by pharmaceutical companies for drug discovery. Comparable as an AI-driven biological simulation platform serving pharma/biotech clients, though focused on immune biology rather than microbiome.
Broad incumbents
- Ginkgo Bioworks: Ginkgo Bioworks is a horizontal synthetic biology platform that designs and programs microbial cells for industrial and biomedical applications. A broad incumbent with a similar platform-plus-applications model but vastly larger scale and capital base.
- Recursion Pharmaceuticals: Recursion uses high-throughput experimental biology combined with AI/ML to discover new therapeutics. Operates a tech-bio platform similar in spirit to Nexilico's digital twin concept, but at much larger scale with publicly disclosed pipeline programs.
- Seres Therapeutics: Seres Therapeutics is a clinical-stage microbiome therapeutics company with an approved product (Vowst) and multiple pipeline programs. A broad incumbent in microbiome drug development with established pharma partnerships and much larger capital base than Nexilico.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Nexilico social profiles
Digital presenceNexilico financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nexilico leadership team
Management profileNumber of profiles
Profiles2 records
Nexilico funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nexilico M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nexilico
What does Nexilico do?
Nexilico develops and operates a proprietary Microbiome Digital Twin Platform—an AI-driven, massively parallel computational platform that simulates the dynamic behavior of microbial communities under perturbations, capturing thousands of metabolic features and tracking strain-level responses over time. The platform powers a modality-agnostic discovery engine for designing precision microbiome therapeutics across multiple disease areas (e.g., necrotizing enterocolitis, drug metabolism, xenobiotic toxicity). It has completed over 1.5 million virtual experiments and 40 billion metabolic calculations, providing biotech, pharma, and research collaborators with in silico prediction capabilities that reduce reliance on costly trial-and-error laboratory studies.
Is Nexilico a public or private company?
Nexilico is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Nexilico founded?
Nexilico was founded in 2019. It employs 1 to 10 people.
Where is Nexilico based?
Nexilico is headquartered in Berkeley, United States, in the North America region.
How does Nexilico make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are collaborative Development Agreements and government Grants and SBIR Funding.
Who are Nexilico's main competitors?
Direct peers on record are Second Genome, Microvi Biotech, Insitro, Siolta Therapeutics and Vedanta Biosciences. Emerging players are Turbine AI and CytoReason. Broad incumbents are Ginkgo Bioworks, Recursion Pharmaceuticals and Seres Therapeutics.
Does Nexilico have an API?
No public API is recorded for Nexilico.
What industry is Nexilico in?
Nexilico's product category is Computational Biology / Microbiome Discovery Platform. Its primary akta.pro industry code is HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.